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Ciglitazone (cig), a thiazolidine-dione, lowers glucose and insulin levels in animal models of diabetes type 
II but not in controls. Since catecholamines given to rat adipocytes in vitro induce insulin resistance similar 
to that seen in type II diabetes in vivo, we measured the effect of cig on mono-A14-[1z~)insulin binding 
and 3-O-methyl-D-glucose transport (GT) in isolated rat adipocytes treated with isoprenaline (iso, 10 FM). 
Cig (< 5 PM) reversed (ED,, 10 nM) the inhibitory effect of iso on insulin stimulation of GT. It had no 
effect on either basal or insulin stimulated GT. Furthermore, cig did not influence insulin binding either 
in the presence or absence of iso, which indicates that cig acts only on a post-insulin receptor level. Cig 
also reversed the inhibiton of GT by both for&Olin, a cyclase activator and R020-1724, an imidazolidine 
phosphodiesterase inhibitor but not that of db-cAMP. It thus seems that cig does not act within the CAMP 
system but only neutralizes its inhibitory effect on the insulin stimulation ofGT. 
Insulin receptor Diabetes Insulin resistance 
1. INTRODUCTION 
Ciglitazone has been reported to be beneficial in 
animal models of type II diabetes, which are 
characterized by resistance to insulin therapy, by 
decreasing hyperglycemia, hypertriglyceridemia 
and hyperinsulinemia and improving the insulin 
tolerance test [1,2]. It had no effect in animal 
models of insulinopenic diabetes or normal 
animals [ 1,2] or on the &cells of the pancreas [ l]. 
The improvement of the diabetic symptoms in type 
II diabetes seems to be mainly due to an effect on 
carbohydrate metabolism. Thus, in a study of 
glucose disposal in ob/ob mice, glucose turnover 
was doubled, gluconeogenesis decreased and 
glucose incorporation in hepatic lipids, glycogen 
Abbreviations: ciglitazone, !I-[4-( l-methylcyclohexyl- 
methoxy)benzyl]-thIaolidine-2,4dione; CAMP, adeno- 
sine cyclic 3 ’ ,5 ‘-monophosphate; db-cAMP, N6,d- 
dibutyryl-CAMP; R020-1724, d-1,4-(3-butoxy-4-meth- 
oxybenzyl)-2-imidazolidinone 
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and protein was increased in the ciglitazone-treated 
animals [3]. Glucose oxidation and incorporation 
in lipids were also increased and potentiated by in- 
sulin in adipocytes from ciglitazone-treated ob/ob 
mice [4]. Insulin sensitivity and responsiveness 
were improved, so that in addition to the observed 
increase in insulin binding an improvement of a 
post-insulin receptor resistance in the diabetic mice 
was postulated [4]. In ciglitazone-treated obese 
Sprague Dawley rats, however, glucose oxidation 
was increased in fat pads but no effect on insulin 
binding was observed. This confirmed the effect 
on glucose metabolism and indicated a direct 
ciglitazone effect on a post-insulin receptor 
resistance independent from insulin binding [5]. 
We showed recently that isoprenaline inhibits in- 
sulin binding and the insulin stimulation of D- 
glucose transport in isolated rat adipocytes [6] via 
a CAMP-dependent mechanism which is probably 
a post-insulin receptor mechanism since it was 
mainly the insulin responsiveness of D-glucose 
transport which was lowered [7]. These 
isoprenaline effects have been reported by other 
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groups too [8,9] and offered a model for the study 
of the post-insulin receptor resistance seen in type 
II diabetes. Here we investigated in vitro the effect 
of ciglitaxone on CAMP-induced insulin resistance 
in isolated rat adipocytes. 
Our results indicate that ciglitazone acts mainly 
by reversing the inhibitory effect of isoprenaline 
on insulin stimulation of the translocation of the 
glucose transporters into the cell membrane. 
2. MATERIALS AND METHODS 
Fat cells were prepared from male Sprague- 
Dawley rats fed ad libitum (180-220 g body 
weight). Krebs-Ringer-Hepes buffer (pH 7.4, 
37’C) containirtg 2.5 g/dI crystalline bovine serum 
albumin was used for all incubations. High CAMP 
levels were achieved as described in [6,7] by a 
30-min preincubation with isoprenaline which was 
carried out in the presence of 16 mM D-glucose to 
stabilize intracellular levels of ATP [6]. 
Ciglitaxone was prepared according to [lo]. In the 
experiments in which the ciglitazone ffects after 
insulin stimulation were studied, isoprenahne 
(lO,uM, Serva, Heidelberg) and adenosine 
deaminase (10 U/ml, Sigma, Munich) were added 
20 min after insulin (0.67 uM) as described in [ 111. 
Forskolin was obtained from Calbiochem, 
Frankfurt, R020-1724 from Hoffmann-LaRoche, 
Grenzach, metformin from Chemiewerk Hom- 
burg, Frankfurt, and gliquidone from Dr K. 
Thomae GmbH, Biberach. 
2.1. 3-O-iUethylglucch9e transport 
3-0-Methylglucose transport was measured as 
described in [14]. Aliquots (100 /cl) of the concen- 
trated cell suspension (5 x lo6 cells/ml) were 
drawn together with 200,ul 3-O-methyglucose 
(final concentration 0.5 mM) and a tracer of 
0.1 /cCi 3-O-methyl-D-[‘4C)gIucose (Radiochemi- 
cal Centre, Amersham) into a mixing pipette 
(Gilson Medical Electronics, France). After 4 s, 
the uptake was stopped by diluting the cells in 5 ml 
NaCl(0.9 g/dl) which contained phloretin (1 mM). 
Cells and medium were separated by centrifuga- 
tion through silicone oil (1000 x g for 60 s). The 
cell layer was removed by a pipette, added to scin- 
tillation fluid, and the radioactivity measured. The 
amount of 3-0-methylglucose in extracellular fluid 
or taken up by diffusion was determined in 
50 
samples which contained 1 mM phloretin. All 
other uptake data were corrected by this value. 
3-O-Methylglucose accumulation measured uring 
4 s is expressed as a percentage of the 3-O-methyl- 
glucose accumulated at equilibrium in fat cells 
after 30 min incubation at saturating insulin con- 
centrations (6.7 nM). 
2.2. Binding studies 
After preincubation of fat cells (4.5-5.5 x 10’ 
cells/ml) 33 or 67 pM mono-A14-[12sI]insulin 
(specific activity 250 pCi/pg, Novo Industrie, 
Bagsvaerd, Denmark) were added alone or 
together with unIabelIed insulin in concentrations 
between 0.1 and 6.7 nM. After 20 min, 400-,ul ali- 
quots were transferred into polyethylene c ntrifuge 
tubes and the cells were separated from the 
medium by centrifugation through dinonylphtha- 
late [14]. The tubes were cut at the oil layer and 
radioactivity of the cell layer was measured. Non- 
specific binding was assessed by addition of un- 
labelled insulin (6.7 ,uM) to the tracer and the value 
was substracted. 
For statistical evaluations the two-tailed Stu- 
dent’s t-test for paired observations was used. 
3. RESULTS AND DISCUSSION 
3.1. Ciglitazone effects on isoprenaline-induced 
insulin resistance 
As described earlier [6], a 30-min preincubation 
with isoprenaline (10 ,uM) inhibits the insulin 
stimulation of D-glucose transport by 45.6 f 5.1% 
in isolated rat adipocytes at insulin concentrations 
exceeding 0.17 nM (fig. 1). The EDSO of insulin 
(0.61 nM) was not changed. In cells treated for 
30 min with isoprenaline as above and ciglitaxone 
(5 PM) the glucose transport values were almost 
equal to control values at the same insulin concen- 
trations (fig.1). Sensitivity of ghicose transport o 
insulin remained unchanged, ciglitaxone only 
reversing the decrease in insulin responsiveness 
caused by isoprenaline. Ciglitazone did not alter 
the basic D-glucose transport (fig.l), suggesting 
that its effect is insulin dependent. The reversal of 
the isoprenalme inhibition of insulin stimuiation of 
D-glucose transport by ciglitaxone was concentra- 
tion dependent (EDSO 10 nM) and maximal at 
about 1 ,uM (fig.2). When given with insulin alone 
ciglitazone had no effect (fig.2). These results ug- 
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Fig.1. Effect of ciglitazone on the isoprenaline-induced 
observations. 
inhibition of insulin stimulation of D-glucose transport 
in isolated rat adipocytes. Epididymal rat adipocytes 
were isolated with the collagenase method and incubated 
in Krebs-Ringer-Hepes buffer (37”C, 16 mM glucose, 
pH 7.4) in the absence (0) or presence of isoprenaline 
(10 PM, (A, A) and ciglitazone (cig, 5 /tM, A) for 
30 min. Then insubn was added in ~on~~atio~ 
between 30 pM to 67 nM to aliquots, and D-glucose 
transport was measured after 20 mm with 3-O- 
methylglucose in 4 s as described in section 2 and 
expressed as a percentage of the ~~~b~~ space fiied 
in 30 min. The data represent the mean of 5 independent 
preparations measured in duplicate. D-Glucose 
transport after preincubation with isoprenaline was 
significantly lower (* P < 0.04) than control at insulin 
concentrations exceeding 0.17 nM. The glucose 
transport after preincubation with isoprenaline and 
ciglitaxone was significantly higher (* P c 0.05) than 
with isoprenaline alone at insulin concentrations 
between 0.17 and 67 nM. Statistical significance was 
calcuiated using the two-tailed Student’s t-test for paired 
gest that even though its action is insulin depen- 
dent, ciglitazone is not a general potentiator of in- 
sulin action [5]. 
Moreover, this effect seemed to be specific for 
ciglitazone, as other oral anti-diabetic agents like 
metformin (4 fig/ml) or gliquidone (10 pg/ml) did 
not remove the inhibition of insulin stimulation of 
glucose transport caused by preincubation with 
isoprenaline (10 FM) for 30 min (n = 6, not 
shown). 
As isoprenaline decreased insulin binding as well 
[6,8], we investigated whether ciglitazone also 
reversed this effect. As shown in fig.3, after 
30 min preincubation isoprenaline (10 @I) 
lowered insulin binding by 33 f 8% at insulin con- 
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Fig.2. Concentration dependence of the ciglitaxone 
effect on the ~opre~~~du~ i~b~on of insulin 
observations. 
stimulation of D-ghmose transport in isolated rat 
adipocytes. Epididymal rat adipocytes were isolated with 
the collagenase method and preincubated in 
Krebs-Ringer-Hepes buffer (37°C 16 mM ghrcose, pH 
7.4) in the presence (W) or absence (o--o) of 
isoprenaline (10 /rM). The ahquots contained cightazone 
in concentrations between 0 and 1 ,uM as indicated on 
the abscissa. After 30 mm, insulin (2 nM) was added 
and D-glucose transport measured after 20 min as 
described insection 2. The data represent the mean f SE 
of 7 independent preparations, each measured in 
duplicate. The D-glucose transport in isoprenaiine- 
treated cells was smaRer than in controls until a 
ciglitaxone concentration of 10 nM (* P < 0.05) was 
reached. At 1 CM ciglitazone, the D-glucose transport 
was higher than the value obtained with isoprenalme 
alone (++P c 0.01). StatisticaL significance was 
calculated using Student’s two-tailed t-test for paired 
centrations below 2 nM [a]. This decrease of high 
affinity binding [6] was not reversed by ciglitazone 
(5 /rM, fig.3). It seems therefore that ciglitazone 
only counteracts the insulin resistance at post 
receptor level. 
Our results thus agree fully with the ones ob- 
tained with ciglitazone-treated obese Sprague- 
Dawley rats [5], where an enhancement of insulin 
induced glucose oxidation but no effect on insulin 
receptors were found. They agree only partly with 
the ones obtained with adipocytes of treated ob/ob 
mice [4], where increased Irwin-indu~ glucose 
oxidation and incorporation in lipids were re- 
ported together with an increase in insulin binding. 
The increase in insulin binding observed in these 
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Fig.3. Effect of ciglitazone on the isoprenaline-induced 
inhibition of insulin binding in isolated rat adipocytes. 
Cells were treated as in fig.1 and binding of mono- 
A14-[1251]insulin wasdetermined as described in section 
2. On the ordinate, the fraction of [‘ZsI]insulin (%) 
which bound on addition of unlabelled insulin as 
indicated on the abscissa isgiven. The data represent the 
mean f SE of 4 independently performed experiments 
measured in duplicate. Ciglitazone had no effect on the 
isoprenaline-induced inhibition of binding between 0.03 
and 0.67 nM insulin. Significance was calculated using 
the two-tailed Student’s t-test for paired observations 
(*+P < 0.01). 
experiments might very well have been due to the 
decrease of hyperinsulinemia which followed the 
improvement of the post-insulin receptor resist- 
ance brought about by ciglitazone and could also 
account for the increase of insulin sensitivity which 
was observed in these experiments but not in ours. 
On a more general scale, glucose transport is 
thought to be rate-limiting for glucose metabolism 
in adipocytes. Our finding that ciglitazone reverses 
post-insulin receptor resistance by counteracting 
the inhibitory effect of catecholamines on insulin 
stimulation of glucose transport could therefore 
explain the improvement in glucose metabolism 
caused by ciglitazone in vivo [l-5]. 
3.2. Possible site of interaction of ciglitazone with 
the glucose transport system 
Having found that ciglitazone removed the in- 
hibition of glucose transport by isoprenaline, we 
went on to investigate how it interacts with the 
glucose transport system. Isoprenaline inhibits in- 
sulin stimulation of D-glucose transport by two 
main mechanisms [6,9]: by inhibiting the 
translocation of glucose transporters from an inner 
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compartment o the cell membrane and by chang- 
ing the affinity of the glucose transporters in the 
cell membrane. When given before insulin, 
isoprenaline lowers the V,,, of glucose transport, 
which means that a smaller number of glucose 
transporters are present in the cell membrane [6,9]. 
When given on the insulin stimulated glucose 
transport, isoprenaline should, according to [9], 
have no effect on translocation, as more than 50% 
of the intracellular glucose transporters are then 
already translocated to the cell membrane causing 
an 8-fold increase of glucose transport [12,13]. 
In our experiments, we added isoprenaline 
(10 PM) and adenosine-deaminase (10 U/ml) 
20 min after insulin (0.67 nM) for 30 min accor- 
ding to [ 1 l]. Glucose transport was then measured 
and a significant decrease of glucose transport by 
54.3 + 19.5% was observed (n = 4, P < 0.01). 
When ciglitazone (1 PM) was added together with 
isoprenaline and adenosine deaminase, the glucose 
transport value improved by 10% which was not 
significant (P < 0.02). This glucose transport value 
was still significantly lower than the control value 
(P c 0.01, n = 4). Since ciglitazone did not reverse 
the isoprenaline effect on insulin stimulated 
glucose transport, one could conclude that it does 
not influence the isoprenaline effect on the affinity 
,of the transporters in the cell membrane but pro- 
bably acts by reversing its inhibitory effect on 
translocation of glucose transporters. 
3.3. Possible site of ciglitazone interaction with 
the CAMP system 
Since the isoprenaline-induced resistance of 
glucose transport has been shown to be mediated 
by CAMP [7], we investigated the ciglitazone effect 
on the CAMP system, even though it is not known 
whether CAMP has a role in the insulin resistance 
of type II diabetes. 
Ciglitazone (1 PM) was given to isolated rat 
adipocytes together with various CAMP 
modulating substances which act at specific points 
of the CAMP system. We reasoned that if 
ciglitazone interferes with the catecholamine recep- 
tor or the regulatory subunits of the adenylate 
cyclase then it should have no effect in the presence 
of forskolin, an agent which directly stimulates the 
catalytical subunit of the adenylate cyclase. If 
ciglitazone acts by stimulating the phosphodiester- 
ase and thereby lowering CAMP, then a phospho- 
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diesterase inhibitor like R020 should prevent the 
ciglitazone effect. If, however, the ciglitazone ac- 
tion should take place at or after the CAMP- 
stimulated protein kinase, then even the effect of 
CAMP analogues like db-CAMP should be anta- 
gonized. As shown in table 1, all the above- 
mentioned substances inhibited the insulin stimula- 
tion of glucose transport to a significant degree. 
Ciglitazone antagonized all of them except db- 
CAMP, which means that it could overcome an in- 
crease in endogenous CAMP but was not effective 
against the exogenously added db-CAMP. This 
could indicate that ciglitazone is a direct com- 
petitor of CAMP on the CAMP-dependent protein 
kinase. This is however unlikely as ciglitazone 
should then antagonize all CAMP effects and also 
reverse the CAMP-induced inhibition of insulin 
binding and of glucose transport after insulin 
stimulation. The interaction with the CAMP 
system thus seems to be limited to the reversal of 
CAMP-mediated inhibition of the translocation of 
glucose carriers to the cell membrane. 
Evidence for an interaction of ciglitazone with 
CAMP in glucose metabolism has also been ob- 
tained in vivo. Thus diabetic ob/ob mice that 
lacked the 20-25% inhibition of glucose 1-14C 
oxidation after epinephrine which was observed in 
control groups reacted to epinephrine like the con- 
trols when they were given ciglitazone [4]_ Ciglita- 
zone, however, had no effect on epinephrine re- 
sponsive metabolic processes like lipolysis in iso- 
lated fat pads of either lean or obese mice [4] in 
vitro, or on the epinephrine-induced hyperglycemia 
and lipolysis in ob/ob mice and controls in vivo 
PI. 
In conclusion, we showed that ciglitazone 
reversed the isoprenaline-induced insulin resistance 
in isolated rat adipocytes as it improved glucose 
metabolism in the animal models of type II 
diabetes in vivo [l-5]. It seems to interfere with 
the CAMP-mediated inhibition of the translocation 
of glucose carriers to the cell membrane, thus 
allowing insulin stimulation of glucose transport 
almost & in the absence of CAMP inhibition. 
Table 1 
Effects of ciglitazone on the CAMP-induced inhibition of insulin stimulation of 
D-glucose transport 
Insulin (2 nM) 
+ addition 
D-Glucose transport (Vo) Ala P 
Without With ciglitazone 
- 43.5 + 6.9 45.8 + 7.6 2.3 f 2.8 ns. 
Isoprenaline 20.1 + 2.3 32.1 & 2.8 12.0 i 3.6 ~0.01 
Forskolin 18.5 -I 5.0 24.7 f 4.6 6.1 f 0.6 ~0.01 
R020 30.6 f 4.0 38.5 + 3.5 7.9 f 2.2 ~0.01 
db-CAMP 21.9 & 0.7 22.2 f 2.4 0.3 + 0.1 n.s. 
’ A’, Difference between absence and presence of ciglitazone 
Epididymal rat adipocytes were isolated with the collagenase method and 
incubated in Krebs-Ringer-Hepes buffer (37’C, 16 mM glucose, pH 7.4) in 
presence or absence of ciglitazone (1 /IM) with isoprenaline (lO/rM), forskolin 
(0.1 mM), RO20 (R020-1724, 1 mM) and db-CAMP (1 mM) for 30 min and 
then insulin (2 nM) was added. After 20 min, D-glucose transport was measured 
in 4 s and expressed as percent of ~u~bri~ uptake of 3-O-m~hylglucose. The 
data represent he mean f SE of 5 independent preparations each measured in 
duplicate. The aliquots which contained CAMP-modulating substances and no 
ciglitazone all had lower glucose transport values (P < 0.01; R020: P < 0.05) 
than the aliquots containing only insulin. When compared to the ones also 
containing ciglitazone, the latter were signifi~tly (P % 0.01) higher, except for 
the aliquot containing db-CAMP or insulin alone. Statistical significance was 
evaluated using the two-tailed Student’s t-test for paired observations 
53 
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